Evidence map›Paper›PMID 36709189›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].

H Ai, R H Mi, L Chen, X Ji, Q S Yin, X D Wei, Y P Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

H AiDepartment of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
R H MiDepartment of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
L ChenDepartment of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
X JiDepartment of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Q S YinDepartment of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
X D WeiDepartment of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
Y P SongDepartment of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, Heterocyclicfms-Like Tyrosine Kinase 3HumansMutationNiacinamidePhenylurea CompoundsProtein Kinase InhibitorsSorafenibSulfonamidesAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicFLT3 protein, humanfms-Like Tyrosine Kinase 3NiacinamidePhenylurea CompoundsProtein Kinase InhibitorsSorafenibSulfonamidesvenetoclax

Identifiers

PMID36709189
PMCPMC9808861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.